Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis.
Schorlemmer
H U
HU
Research Laboratories Hoechst Marion Roussel Deutschland GmbH, Wiesbaden, Germany.
Bartlett
R R
RR
Schleyerbach
R
R
D020106:Acrylamide / Q000627:therapeutic use; D000178:Acrylamides; D000480:Alkynes; D000818:Animals; D000974:Antibodies, Antinuclear / Q000097:blood; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D002208:Caproates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007555:Isoxazoles; D051379:Mice; D008817:Mice, Mutant Strains; D009570:Nitriles; D051381:Rats; D011917:Rats, Inbred Lew
D000178:Acrylamides; D000480:Alkynes; D000974:Antibodies, Antinuclear; D002208:Caproates; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; D020106:Acrylamide; C116406:HMR 1279